AcelRx Pharmaceuticals Inc

Stock Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Presents Results from Phase 3 Study of ARX‑04

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced that the Company and its investigators will be presenting Phase 3 SAP301 study results at Euroanaesthesia 2016, which is …

Corey Williams — May 26, 2016, 7:32 AM EDT

Stock Update (NASDAQ:ACRX): New Study of AcelRx Pharmaceuticals Inc Reveals Cost of Initial IV Opioid Dose in the Emergency Department for the Treatment of Acute Pain Exceeds $140

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) reported that the Company will be presenting an evaluation of the cost of delivering IV opioids in the emergency department …

Corey Williams — May 24, 2016, 8:02 AM EDT

Company Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Advances ARX-04 into Extension Phase of Open-Label Phase 3 Emergency Room Study

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, …

Corey Williams — March 14, 2016, 8:07 AM EDT

Stock Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Provides Corporate Update and Reports Fourth Quarter and Full Year 2015 Financial Results

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today …

Corey Williams — March 7, 2016, 4:08 PM EDT

Stock Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc’s Moderate-to-Severe Acute Pain Candidate ARX-04 Shows Improved Pain Scores in ER Patients in Interim Phase 3 Analysis

Corey Williams — February 25, 2016, 8:10 AM EDT

Company Update (ACRX): AcelRx Pharmaceuticals Inc Announces Anticipated 2016 Milestones

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, announced …

Corey Williams — January 10, 2016, 7:10 AM EDT

Company Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Completes Protocol Review with FDA and Plans to Initiate Phase 3 Open-Label Study or Zalviso

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today …

Corey Williams — January 8, 2016, 7:10 AM EDT

Company Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Receives Notice of Eligibility for Centralized Review of ARX-04 from European Medicines Agency

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the intended treatment of acute …

Corey Williams — December 23, 2015, 7:22 AM EDT

Stock Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Conducts Pre-NDA Meeting with U.S. Food and Drug Administration for ARX-04

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies designed for the treatment of acute pain, …

Corey Williams — December 14, 2015, 7:22 AM EDT

Stock Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Announces Sublingual Sufentanil Data Presentation at the American Society of Regional Anesthesia and Pain Medicine Meeting

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, announced …

Corey Williams — November 19, 2015, 7:29 AM EDT

« 1 2 3 4 5 6 »

AcelRx Pharmaceuticals Inc

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts